ACE Biosciences and Aeras Global TB Vaccine Foundation enter tubercolosis vaccine collaboration
The current TB vaccine, BCG, does not provide good protection against pulmonary TB in adults or children. Aeras is working on a range of second-generation BCG vaccines with the aim of enhancing the protection they afford and introducing other improvements such as patient-friendly delivery options. As part of this programme, Aeras has developed secondgeneration recombinant BCG strains where specific proteins have been introduced or the expression of existing proteins has been enhanced.
Under the terms of the agreement, Aeras has approached ACE BioSciences to apply its analytical tools to identify and characterise the proteins in these recombinant BCGbased TB vaccines. This research will enable Aeras to understand and refine its developmental vaccines and it will underpin the manufacture of promising candidates. Financial details of the collaboration were not disclosed.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.